TICKERNERD
Menu
IVFHealthcare · Medical Devices

IVF Stock Forecast: INVO Fertility, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.74
+0.28% on the day

The 1 Wall Street analysts covering INVO Fertility, Inc. hold a median 12-month price target of $20 — +2602.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.4M
Ticker Nerd rank
31 / 100
Median analyst target
$20
Analysts covering
1
Revenue$2.2M+16.7% y/y
Operating income−$1.3M
Net income$889K
Free cash flow−$1.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.9%
1M
−24.6%
YTD
−80.3%
1Y
−97.8%
From 52W high
−98.7%
From 52W low
+0.3%
$1
$56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IVF stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores INVO Fertility, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Growth
96
Volatility
52
Issuance
49
Accruals
36
Momentum
27
Revisions
25
Value
14
Quality
14

Size (97): Smaller than most of the companies we track.

Quality (14): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IVF stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IVF, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26IVFHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $20Median $20High $20

The green dot is the last close — the median target sits +2602.3% from it.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IVF appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IVF vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, INVO Fertility, Inc. returned −97.8% against +16.2% for the S&P 500, dividends included.

IVF vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26IVFS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IVF analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

INVO Fertility, Inc. (IVF) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
0.5×

Cheaper than 82% of US stocks

Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
−0.5×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
16.7%

Higher than 65% of US stocks

Earnings growth (YoY)
—
Gross margin
35.1%

Higher than 42% of US stocks

Operating margin
−59.3%

Higher than 16% of US stocks

Net margin
−92.3%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−72.7%

Higher than 17% of US stocks

Return on assets
−16.4%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

INVO Fertility, Inc. (IVF) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • INVO Fertility, Inc. has a market value of $3.4M and an enterprise value of $2.4M.

  • Revenue in the twelve months to 30 June 2026: $7.5M. The latest quarter grew 16.7% year on year.

  • Net income over the same four quarters: −$5.3M, a −70.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$4.8M.

  • INVO Fertility, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 1.9M.

  • Trailing P/E: 0.0×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • INVO Fertility, Inc. employs 40 people — $188K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

IVF vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
IVFINVO Fertility, Inc.$3.4M
31
BJDXBluejay Diagnostics, Inc.$3.6M
17
NXLNexalin Technology, Inc.$3.4M
33
ICCMIceCure Medical Ltd.$3.9M
38
POASPhaos Technology Holdings (Cayman) Ltd.$4.5M
2
ADGMAdagio Medical Holdings, Inc.$2.8M
34
AIDX20/20 Biolabs, Inc.$4.6M
3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own INVO Fertility, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IVF news & analysis

INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference

GlobeNewsWire · 25 Sept 2026neutral

INVO Fertility, Inc. announced it will participate in the Lytham Partners Fall 2026 Investor Conference, delivering a webcast presentation and hosting one-on-one meetings with investors virtually on September 29-30, 2026. The announcement was made from the company's Sarasota, Florida headquarters.

Why it matters — The company's involvement in the investor conference provides an opportunity to present its business and engage directly with the investment community.

INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

GlobeNewsWire · 28 Aug 2026neutral

INVO Fertility announced it will participate in H.C. Wainwright's 28th Annual Global Investment Conference, with a virtual company presentation available starting September 11, 2026 at 7:00 a.m. ET.

Why it matters — The presentation provides an opportunity for investors and industry watchers to learn about INVO Fertility directly from the company at a major investment conference.

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

GlobeNewsWire · 20 Aug 2026positive

INVO Fertility announced five poster presentations highlighting platelet-rich plasma research at the 2026 Midwest Reproductive Symposium International. The announcement was made by Gretchen Collins, M.D.

Why it matters — The poster presentations showcase the company's research activity in platelet-rich plasma, a topic of interest to fertility-industry watchers.

INVO Fertility Stock Surges Following Q2 Earnings Beat

Benzinga · 17 Aug 2026positive

INVO Fertility Inc. saw its shares rise Monday afternoon after reporting second-quarter financial results that significantly beat Wall Street expectations on bottom-line earnings.

Why it matters — The stronger-than-expected quarterly earnings signal that INVO Fertility's financial performance is exceeding analyst forecasts, a key indicator for investors tracking the company.

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

GlobeNewsWire · 17 Aug 2026positive

INVO Fertility reported second quarter 2026 financial results, with revenue increasing 17% year over year as the company advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices. The company also reported that its clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses.

Why it matters — The 17% revenue growth and clinic platform profitability provide an indicator of the company's operational and financial performance for watchers of INVO Fertility.

FAQ

Frequently asked questions about IVF stock

What is the IVF stock price forecast for 2026-2027?

The 1 Wall Street analysts covering INVO Fertility, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IVF stock a buy right now?

Of the 1 analysts covering INVO Fertility, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks INVO Fertility, Inc. 31 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IVF?

As at 8 Oct 2026, INVO Fertility, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will IVF stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +2602.3% from the last close, and Ticker Nerd's factor model ranks INVO Fertility, Inc. 31 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IVF stock forecast for 2030?

No analyst covering INVO Fertility, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IVF are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has IVF stock performed over the past year?

INVO Fertility, Inc. returned -97.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does INVO Fertility, Inc. do?

INVO Fertility Inc. is a healthcare services company focused on assisted reproductive technology and women’s fertility care.

What is the latest news on IVF?

The most recent item we track (GlobeNewsWire, 25 Sept 2026): "INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference". INVO Fertility, Inc. announced it will participate in the Lytham Partners Fall 2026 Investor Conference, delivering a webcast presentation and hosting one-on-one meetings with investors virtually on September 29-30, 2026. The announcement was made from the company's Sarasota, Florida headquarters.

Company

About INVO Fertility, Inc.

INVO Fertility Inc. is a healthcare services company focused on assisted reproductive technology and women’s fertility care. The company operates fertility clinics and related service offerings that support patients seeking infertility treatment, including in vitro fertilization and the intravaginal culture procedure enabled by its INVOcell medical device. INVO Fertility also commercializes INVOcell for use in third-party clinics, extending its technology platform beyond owned locations. Its business is centered on making fertility treatment more accessible through a combination of clinic operations, proprietary devices, and patient-centered care delivery. Headquartered in Sarasota, Florida, INVO Fertility serves the reproductive health market with a model that blends medical technology and clinical services.

CEO Mr. Steven M. Shum · 40 employees · United States · https://www.invofertility.com